99mTc-rituximab radiolabelled by photo-activation: A new non-Hodgkin's lymphoma imaging agent

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 33, Issue 1, 2006, Pages 53-59

  Gmeiner Stopar, T ^a   Mlinaric Rascan, I ^b   Fettich, J ^a   Hojker, S ^a   Mather, S J ^c  

^a UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

^b UNIVERSITY OF LJUBLJANA   (Slovenia)

^c ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

99mTc; Antibody; CD20; Lymphoma; Radioimmunoscintigraphy; Radiolabelling

Indexed keywords

CD20 ANTIBODY; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT; RITUXIMAB TC 99M; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ARTICLE; BINDING ASSAY; CANCER DIAGNOSIS; CANCER INVASION; CANCER RECURRENCE; CANCER REGRESSION; CANCER STAGING; CONTROLLED STUDY; DRUG PURIFICATION; DRUG UPTAKE; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; IN VITRO STUDY; INTERNALIZATION; ISOTOPE LABELING; METASTASIS; NONHODGKIN LYMPHOMA; PHOTOACTIVATION; RADIOCHEMISTRY; RADIOIMMUNOTHERAPY; ULTRAVIOLET RADIATION;

ANTIBODIES, MONOCLONAL; CELL LINE, TUMOR; DRUG STABILITY; FEASIBILITY STUDIES; HUMANS; LYMPHOMA, B-CELL; ORGANOTECHNETIUM COMPOUNDS; PHOTOCHEMISTRY; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; STAINING AND LABELING; ULTRAVIOLET RAYS;

EID: 28944433571     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-005-1838-4     Document Type: Article

References (35)

1. Golay J, Gramigna R, Facchinetti V, Capello D, Gaidano G, Introna M. Acquired immunodeficiency syndrome-associated lymphomas are efficiently lysed through complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity by rituximab. Br J Haematol 2002; 119:923-9
2. Cragg MS, Walshe CA, Ivanov AO, Glennie MJ. The biology of CD20 and its potential as a target for mAb therapy. Curr Dir Autoimmun 2005;8:140-74
3. Coffey J, Hodgson DC, Gospodarowicz MK. Therapy of non-Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging 2003;30Suppl 1:S28-36
4. Gopal AK, Press OW. Clinical applications of anti-CD20 antibodies. J Lab Clin Med 1999;134:445-50
5. Tallman MS. Monoclonal antibody therapies in leukemias. Semin Hematol 2002;39 4:12-9
6. Withoff S, Bijman MNA, Stel AJ, Delahaye L, Calogero A, de Jonge MWA, et al. Characterization of BIS20x3, a bi-specific antibody activating and retargeting T-cells to CD20-positive B-cells. Br J Cancer 2001;84:1115-21
7. Avivi I, Robinson S, Goldstone A. Clinical use of rituximab in haematological malignacies. Minireview. Br J Cancer 2003;89:1389-94
8. Johnson PWM, Glennie MJ. Rituximab: mechanisms and application. Br J Cancer 2001;85 11:1619-23
9. http://www.emea.eu.int/humandocs/Humans/EPAR/Mabthera/Mabthera.htm. Accessed January 15, 2004
10. Emmanouilides C. Current status of radioimmunotherapy for non-Hodgkin lymphoma. Haema 2003;6:314-27
11. 131I)anti-B1 (anti-CD20) antibody. N Engl J Med 1993;329:459-65
12. http://www.rxlist.com/cgi/rxlist.cgi?drug=rituximab. Accessed December 15, 2004
13. Swerdlow AJ. Epidemiology of Hodgkin's disease and non-Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging 2003;30 Suppl 1:S2-12
14. Hoskin PJ, O'Doherty MJ. Lymphoma: diagnosis and management introduction. Eur J Nucl Med Mol Imaging 2003; 30 Suppl 1:S1
15. Even-Sapir E, Israel O. Gallium-67 scintigraphy: a cornerstone in functional imaging of lymphoma. Eur J Nucl Med Mol Imaging 2003;30 Suppl 1:S65-81
16. Hoskin PJ. PET in lymphoma: what are the oncologist's needs? Eur J Nucl Med Mol Imaging 2003;30 Suppl 1:S37-41
17. Rankin SC. Assessment of response to therapy using conventional imaging. Eur J Nucl Med Mol Imaging 2003;30 Suppl 1: S56-64
18. Sciepers C, Filmont JE, Czernin J. PET for staging of Hodgkin's disease and non-Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging 2003;30 Suppl 1:S82-8
19. Vinnicombe SJ, Reznek RH. Computerised tomography in the staging of Hodgkin's disease and non-Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging 2003;30 Suppl 1:S42-55
20. Reske SN. PET and restaging of malignant lymphoma including residual masses and relapse. Eur J Nucl Med Mol Imaging 2003;30 Suppl 1:S82-96
21. 18F]FDG for therapy response monitoring in lymphoma patients. Eur J Nucl Med Mol Imaging 2003;30 Suppl 1:S97-105
22. 99mTc-labelled monoclonal antibodies: a review. Nucl Med Commun 1993;14:347-59
23. Mather SJ. Radiolabelled antibodies and peptides. In: Sampson CB, editor. Textbook of radiopharmacy theory and practice. 3rd ed. Amsterdam, The Netherlands: Gordon and Breach Science Publishers; 1990. p. 63-82
24. Urbain JLC, Vekemans MCM, Lemieux SK, Cosenza SC, Senadhi VK, Milestone BN, et al. Nuclear oncology and the imagine concept. Acta Radiol 1997;38 Suppl 41:21-8
25. Stalteri MA, Mather SJ. Technetium-99m labelling of the anti-tumour antibody PR1A3 by photoactivation. Eur J Nucl Med 1996;23:178-87
26. Muddukrishna SN, Chen A, Qi P, Smolenski MA. Quantitation of reduced disulfide groups in monoclonal antibodies using 5-iodoacetamidofluorescein: a novel size exclusion-HPLC technique. Appl Radiat Isotopes 1995;46:1015-26
27. Lindmo T, Boven E, Cuttitta F, Fedorko J, Bunn PA Jr. Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J Immunol Methods 1984;72:77-89
28. Badger CC, Krohn KA, Bernstein ID. In vitro measurement of avidity of radioiodinated antibodies. Nucl Med Biol 1987;14:605-10
29. Divgi CR. Status of radiolabeled monoclonal antibodies for diagnosis and therapy of cancer. Oncology 1996;10:939-58
30. Juweid ME. Radiotherapy of B-cell non-Hodgkin's lymphoma: from clinical trials to clinical practice. J Nucl Med 2002;43:1507-29
31. Michel RB, Mattes MJ. Intracellular accumulation of the anti-CD20 antibody 1F5 in B-lymphoma cells. Clin Cancer Res 2002;8:2701-13
32. Press OW, Farr AG, Borroz KI, Anderson SK, Martin PJ. Endocytosis and degradation of monoclonal antibodies targeting human B-cell malignancies. Cancer Res 1989;49:4906-12
33. Jilani I, O'Brien S, Manshuri T, Thomas DA, Thomazy VA, Imam M, et al. Transient down-modulation of CD20 by rituximab in patients with chronic lymphocytic leukemia. Blood 2003;102:3514-20
34. 131I-rituximab: relationship between immunoreactivity and specific activity. J Nucl Med 2004;45:1784-90
35. 131I-labelled anti-CD20 MAB IDEC-C2B8 (rituximab) in relapsed non-Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging 2002;29:1276-82